AC Immune (NASDAQ:ACIU) Given Buy Rating at BTIG Research

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a research report issued on Wednesday, Benzinga reports. They presently have a $8.00 price objective on the stock. BTIG Research’s price target would indicate a potential upside of 200.75% from the stock’s previous close.

A number of other research analysts also recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of AC Immune in a report on Wednesday, August 5th. HC Wainwright restated a “buy” rating on shares of AC Immune in a report on Monday, August 24th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

AC Immune Trading Down 6.0%

NASDAQ:ACIU traded down $0.17 during mid-day trading on Wednesday, reaching $2.66. 265,280 shares of the company’s stock traded hands, compared to its average volume of 274,636. AC Immune has a 12-month low of $2.10 and a 12-month high of $4.00. The firm has a market capitalization of $270.71 million, a price-to-earnings ratio of -4.93 and a beta of 1.60. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.93 and a quick ratio of 1.02. The company has a 50 day moving average price of $2.55 and a 200-day moving average price of $2.68.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%.The company had revenue of $18.67 million for the quarter, compared to the consensus estimate of $9.59 million. On average, sell-side analysts predict that AC Immune will post -0.6 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. AXQ Capital LP purchased a new position in shares of AC Immune during the 2nd quarter worth approximately $25,000. Dimensional Fund Advisors LP grew its holdings in shares of AC Immune by 82.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after acquiring an additional 176,701 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of AC Immune by 8.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after acquiring an additional 30,035 shares during the period. Hedge funds and other institutional investors own 51.36% of the company’s stock.

Key Stories Impacting AC Immune

Here are the key news stories impacting AC Immune this week:

• Positive Sentiment: Part 1 of the VacSYn Phase 2 trial met all primary safety and immunogenicity endpoints through week 100. ACI-7104 was generally safe and well tolerated, produced a 100% antibody response after three immunizations, and showed antibody penetration into cerebrospinal fluid along with signals of target engagement. AC Immune Phase 2 trial announcement
• Positive Sentiment: The results strengthen investor confidence in AC Immune’s approach to targeting alpha-synuclein, a protein associated with Parkinson’s disease, and provide support for advancing ACI-7104 toward later-stage development. AC Immune durable immunogenicity report
• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set an $8 price target, while H.C. Wainwright maintained its Buy rating and $12 target. The targets imply substantial upside from the stock’s recent trading level and signal continued analyst optimism. H.C. Wainwright AC Immune rating
• Neutral Sentiment: Part 1 primarily evaluated safety and immune response. Part 2 is intended to assess clinical activity and determine whether ACI-7104 should advance to Phase 3; discussions with the FDA are expected in early 2027. AC Immune Parkinson’s vaccine results
• Negative Sentiment: Despite the favorable data and analyst support, the stock is trading lower, suggesting investors may be taking profits after the initial trial-driven rally or waiting for evidence of meaningful clinical benefit. The absence of Phase 2 efficacy results remains a key risk.

About AC Immune

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.